Trial Profile

A phase I study of Human Pharmacokinetics and Safety of ORY-1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iadademstat (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
Acronyms FiM
Sponsors Oryzon

Most Recent Events

15 Oct 2020 According to an Oryzon media release, data from this study was published in Journal of Clinical Oncology.
15 Oct 2020 Results published in the Oryzon Media Release
30 Jan 2017 According to an Oryzon Genomics media release, top line results of this trial will be summarized at the Keystone Symposia on Epigenetics and Human Disease 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com